Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-like containing PHD and RING finger domain 1 (UHRF1) is an epigenetic regulator and E3 ubiquitin ligase involved in the maintenance of DNA methylation, histone modification, and chromatin structure. It recognizes hemi-methylated DNA and recruits DNA methyltransferases (notably DNMT1) during DNA replication to preserve epigenetic marks[1][2][3]. UHRF1 functions as a master coordinator of multiple chromatin-modifying proteins and plays a crucial role in cell cycle control and tumor suppressor gene silencing through epigenetic mechanisms[2]. Aberrant overexpression of UHRF1 is observed in multiple types of cancer and is associated with poor prognosis, making it both a promising therapeutic target and a biomarker for diagnosis and prognosis in oncology[1][2][3]. UHRF1 exerts non-enzymatic reader functions via multiple domains (UBL, TTD, PHD, SRA, RING) to interact with histone modifications and DNA, orchestrating silencing of tumor suppressor genes and maintenance of epigenetic states[2][3].
Inhibition of E3 ubiquitin ligase activity; Disruption of DNA methylation maintenance; Inhibition of protein-protein interactions with DNMT1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-like containing PHD and RING finger domain 1 (UHRF1).